British Cannabis™ is celebrating its breakthrough of having 1,472 of its products successfully passing onto the crucial next stage of the UK Novel Foods process for CBD food supplements.
British Cannabis™ now has a 12.4 per cent share of the UK market by choice of products.
The Food Standards Agency’s public list has grown substantially from 3,536 individual products in March, to 11,908 now either carrying a ‘Validated’ or ‘Awaiting Evidence’ status. Having 1,472 unique products across many thorough applications gives British Cannabis™ the highest number of CBD food supplement products permitted for general sale of any brand or manufacturer.
British Cannabis’ products on the list include 75 of the company’s own-brand portfolio, from the CBD by British Cannabis™ (FKA Canabidol™), Access CBD® and CBD Health™ ranges.
Read more: EFSA puts CBD Novel Foods evaluations on hold due to lack of data
The company has highlighted that hundreds of individual products across several leading brands ‘Powered by BRITISH CANNABIS’ under the company’s white label manufacturing services are also progressing on towards the validation stage of the Novel Foods application process.
British Cannabis™ CEO, Thomas Whettem, commented: “This is a monumental moment for our company and a recognition of three years of work and investment from myself and our dedicated project team. Our aim from the start in 2015 has been to act as an authority when it comes to CBD products that people can trust. Now, having cornered the market with nearly one-in-ten of the CBD products remaining legal to sell in the UK, I am galvanised that we are on our way to achieving this goal.
“We had 15 individual Novel Foods dossier submissions to the FSA, spanning thousands of pages and many hours of providing evidence. This gave us a substantial 20 per cent of all of the RP numbers now appearing on this public list.
“The evidence gathered included our thorough testing, product safety and purity, and our passion for compliant products that do and contain what we say they do. It’s our vision that retailers and consumers alike will be able to continue to place their trust in British Cannabis™ for many years to come.”
Read more: Novel Foods applicant responds to EFSA’s decision to pause evaluations
On Thursday 30 June 2022, the UK’s Food Standards Agency published its final update to the public list of CBD food products linked to novel food applications. The list of products has grown substantially from 3,536 individual products in March, to 11,908 now either carrying a ‘Validated’ or ‘Awaiting Evidence’ status.
British Cannabis™ products are among the few remaining on the market to use 100 per cent cannabis, naturally derived formulas in their CBD oils. The company states these products contain the hundreds of clinically proven plant phytochemicals found in cannabis whilst also being 0 per cent THC, and that its food supplements are also free from other restricted cannabinoids.
Managing director, David Ralson, stated: “I can hardly put into words how excited and proud this announcement makes me, both for my team and for all of the customers that support our products.
“To be confirmed at this time as the most predominate manufacturer in the UK for the number of products on the FSA public list is gratifying for all of the dedication we have put into doing things the best way possible and in order to make our products sustainable for the future.
“Our partners at the ACI (Association for The Cannabinoid Industry) have been supporting us in progressive communication along the way with both the FSA and Trading Standards. As soon as the consortium toxicology study that we have partaken in with the ACI and its members is ready for release, we look forward to our products currently listed as ‘Awaiting Evidence’ on the public list to move on to Validated status, and then to full approval in the next year or two.
“I would encourage all of our customers and consumers, existing and future, to check the FSA public list carefully; is your CBD supplement on the list? If not, why? Our Primary Partnership with Berkshire & Buckinghamshire Trading Standards sees us ready to advise retailers who have questions about this process and what compliant CBD products they should be stocking.
“Moving forward, we are delighted to be able to offer them a greater choice of compliant cannabis food products than any other manufacturer.”
[activecampaign form=31]
